V Gödecke1, J J Schmidt2, J H Bräsen3, C Koenecke4, H Haller2. 1. Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. goedecke.vega@mh-hannover.de. 2. Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. 3. Institut für Pathologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland. 4. Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
Abstract
BACKGROUND: Kidney involvement is a common complication in patients with plasma cell diseases. OBJECTIVE: This article outlines the spectrum of renal involvement in plasma cell dyscrasia and describes diagnostic and therapeutic measures to guide clinical management. MATERIAL AND METHODS: Evaluation and discussion of the current literature as well as existing guidelines and recommendations of professional societies. RESULTS: The clinical manifestations of renal involvement in plasma cell disorders are heterogeneous and range from acute cast nephropathy in multiple myeloma to rare forms of glomerulonephritis. The term monoclonal gammopathy of renal significance (MGRS) was introduced to describe kidney involvement caused by monoclonal gammopathy but without evidence for underlying malignancy. Light chain cast nephropathy is the most common renal manifestation in multiple myeloma, whereas monoclonal immunoglobulin deposition disease (MIDD) and renal light chain (AL) amyloidosis can be found in multiple myeloma and MGRS. Decisive is the extended hematological diagnostics in order to exclude the presence of a hematological neoplasm. The treatment of renal involvement in monoclonal gammopathies involves the reduction of the plasma cell clone with cytoreductive treatment. The reduction of the monoclonal protein in serum is prognostically relevant for the renal response to treatment. In the case of histological evidence of a light chain cast nephropathy, high cut-off dialysis is recommended to reduce the free light chains in serum. CONCLUSION: The spectrum of renal manifestations in plasma cell dyscrasia has been expanded, particularly since the introduction of the term MGRS. Diagnostic and therapeutic management remain an interdisciplinary challenge.
BACKGROUND:Kidney involvement is a common complication in patients with plasma cell diseases. OBJECTIVE: This article outlines the spectrum of renal involvement in plasma cell dyscrasia and describes diagnostic and therapeutic measures to guide clinical management. MATERIAL AND METHODS: Evaluation and discussion of the current literature as well as existing guidelines and recommendations of professional societies. RESULTS: The clinical manifestations of renal involvement in plasma cell disorders are heterogeneous and range from acute cast nephropathy in multiple myeloma to rare forms of glomerulonephritis. The term monoclonal gammopathy of renal significance (MGRS) was introduced to describe kidney involvement caused by monoclonal gammopathy but without evidence for underlying malignancy. Light chain cast nephropathy is the most common renal manifestation in multiple myeloma, whereas monoclonal immunoglobulin deposition disease (MIDD) and renal light chain (AL) amyloidosis can be found in multiple myeloma and MGRS. Decisive is the extended hematological diagnostics in order to exclude the presence of a hematological neoplasm. The treatment of renal involvement in monoclonal gammopathies involves the reduction of the plasma cell clone with cytoreductive treatment. The reduction of the monoclonal protein in serum is prognostically relevant for the renal response to treatment. In the case of histological evidence of a light chain cast nephropathy, high cut-off dialysis is recommended to reduce the free light chains in serum. CONCLUSION: The spectrum of renal manifestations in plasma cell dyscrasia has been expanded, particularly since the introduction of the term MGRS. Diagnostic and therapeutic management remain an interdisciplinary challenge.
Authors: Colin A Hutchison; Vecihi Batuman; Judith Behrens; Frank Bridoux; Christophe Sirac; Angela Dispenzieri; Guillermo A Herrera; Helen Lachmann; Paul W Sanders Journal: Nat Rev Nephrol Date: 2011-11-01 Impact factor: 28.314
Authors: Colin A Hutchison; Paul Cockwell; Steven Reid; Katie Chandler; Graham P Mead; John Harrison; John Hattersley; Neil D Evans; Mike J Chappell; Mark Cook; Hermann Goehl; Markus Storr; Arthur R Bradwell Journal: J Am Soc Nephrol Date: 2007-01-17 Impact factor: 10.121
Authors: Samih H Nasr; Anthony M Valeri; Sanjeev Sethi; Mary E Fidler; Lynn D Cornell; Morie A Gertz; Martha Lacy; Angela Dispenzieri; S Vincent Rajkumar; Robert A Kyle; Nelson Leung Journal: Am J Kidney Dis Date: 2012-03-13 Impact factor: 8.860
Authors: Morie A Gertz; Nelson Leung; Martha Q Lacy; Angela Dispenzieri; Steven R Zeldenrust; Suzanne R Hayman; Francis K Buadi; David Dingli; Philip R Greipp; Shaji K Kumar; John A Lust; S Vincent Rajkumar; Stephen J Russell; Thomas E Witzig Journal: Nephrol Dial Transplant Date: 2009-04-29 Impact factor: 5.992
Authors: Taxiarchis V Kourelis; Samih H Nasr; Angela Dispenzieri; Shaji K Kumar; Morie A Gertz; Fernando C Fervenza; Francis K Buadi; Martha Q Lacy; Stephen B Erickson; Fernando G Cosio; Prashant Kapoor; John A Lust; Suzanne R Hayman; Vincent Rajkumar; Steven R Zeldenrust; Stephen J Russell; David Dingli; Yi Lin; Wilson Gonsalves; Elizabeth C Lorenz; Ladan Zand; Robert A Kyle; Nelson Leung Journal: Am J Hematol Date: 2016-08-29 Impact factor: 10.047
Authors: Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp Journal: Mayo Clin Proc Date: 2003-01 Impact factor: 7.616